As Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) recently shared contrasting updates regarding their investigational oral GLP-1 drugs - Pfizer with a setback and Lilly with promising results - Lexaria Bioscience Corp. (LEXX) believes its proprietary DehydraTECH drug delivery technology could be of value to both companies.
On April 14, 2025, Pfizer announced the termination of its development program for Danuglipron as a once-daily oral GLP-1 therapy after a trial participant experienced a liver injury potentially linked to the drug. This follows an earlier setback in December 2023, when the company halted development of a twice-daily version of the same drug due to adverse side effects.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.